Individualized dosing with axitinib: rationale and practical guidance.
Affiliation1 Clinical Division of Oncology, Department of Medicine I & Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 2 Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy. 3 Institute of Cancer Sciences, University of Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, UK. 4 Department of Medical Oncology, St Vincent's University Hospital & The Adelaide & Meath Hospital, Dublin, Ireland. 5 Renal Cancer Unit, Department of Medicine, Royal Marsden Hospital, London, UK. 6 Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. 7 Medical Oncology Department, University of Lyon, Centre Léon Bérard, Lyon, France.
renal cell carcinoma
MetadataShow full item record
PublisherFuture Science Group
AbstractAxitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures have demonstrated high interpatient variability in patients receiving the 5 mg twice-daily (b.i.d.) starting dose. Clinical criteria can be used to assess whether individual patients may benefit further from dose modifications, based on their safety and tolerability data. This review provides practical guidance on the 'flexible dosing' method, to help physicians identify who would benefit from dose escalations, dose reductions or continuation with manageable toxicity at the 5 mg b.i.d. dose. This flexible approach allows patients to achieve the best possible outcomes without compromising safety.
SponsorsThis review was sponsored by Pfizer Pharma GmbH. M Schmidinger has received speaker honoraria and consultancy fees from Pfizer Pharma GmbH, Roche, Bristol-Myers Squibb, Exelixis, Novartis and Astellas. R Danesi has received honoraria and consultancy fees from Pfizer Pharma GmbH, Amgen, Roche, Novartis, Lilly and Celgene and research funding from Pfizer Pharma GmbH and Roche. R Jones has received publication support, speaker honoraria, advisory board membership and research funding from Pfizer Pharma GmbH and GSK, speaker honoraria and research funding from Novartis, advisory board membership from Bristol-Myers Squibb, and advisory board membership and research funding from Roche. R McDermott has received honoraria and research funding from Pfizer Pharma GmbH, Novartis, GSK and Roche. L Pyle has received honorarium from Pfizer Pharma GmbH. B Rini has received research funding and consultancy fees from Pfizer Pharma GmbH. S Negrier has received honoraria from Pfizer Pharma GmbH, ´ Novartis and Bristol-Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Writing assistance was utilized in the production of this manuscript. In development of the manuscript, medical writing support was provided by H Attisha, PhD of Chameleon Communications, with the financial support of Pfizer Pharma GmbH.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
- Authors: Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI
- Issue date: 2013 May
- Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
- Authors: Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E, Schmidinger M
- Issue date: 2014 Apr
- Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
- Authors: Umeyama Y, Shibasaki Y, Akaza H
- Issue date: 2017 Sep
- Axitinib for the treatment of advanced renal cell carcinoma.
- Authors: Akaza H, Fukuyama T
- Issue date: 2014 Feb
- Axitinib: in advanced, treatment-experienced renal cell carcinoma.
- Authors: Yang LP, McKeage K
- Issue date: 2012 Dec 24